News

Hims & Hers’ stock plunges. Here’s why Wegovy parent ended its partnership with the company.
Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...
Novo Nordisk Abruptly Ends Partnership with Hims, Claiming ‘Sham Compounding’ GLP-1 Drugs
The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...
Hims & Hers stock drops after Wegovy manufacturer ends deal to distribute weight loss drug
Novo Nordisk has announced it is ending its distribution collaboration with US telehealth firm Hims & Hers Health over the ...
Why Hims & Hers Health Stock Is Crashing Today
The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...
Daily Voice on MSN17h
Plainsboro-Based Wegovy Provider Ends Hims & Hers Deal Over Knockoff Weight-Loss Drug Sales
Novo Nordisk has ended its partnership with Hims & Hers Health after two months, accusing the telehealth company of pushing ...
Zacks Investment Research on MSN4d
Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?
Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its ...
Hims & Hers Health (NYSE:HIMS) Reports Q1 2025 Earnings Doubling Sales & Net Income
Hims & Hers Health (NYSE:HIMS) recently announced the introduction of affordable access to Wegovy, a significant move aimed at improving obesity treatment options. This, along with strong Q1 2025 ...